In conclusion, this is the first study that has demonstrated and quantified spatial heterogeneity of HER2 expression in GC and showed preferential expression of HER2 in the luminal and lateral parts of the tumor, supporting the validity of using endoscopic biopsy samples for HER2 testing. The gene discussed is ERBB2; the disease is neoplasm.